The history of rubella and rubella vaccination leading to elimination

Clinical Infectious Diseases

Volumn 43, Issue SUPPL. 3, 2006, Pages

  Plotkin, Stanley A ^a,b  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b SANOFI PASTEUR   (France)

Author keywords

[No Author keywords available]

Indexed keywords

MEASLES MUMPS RUBELLA VACCINE; RUBELLA VACCINE;

CONGENITAL RUBELLA SYNDROME; DEVELOPED COUNTRY; HISTORY; HUMAN; INFECTION CONTROL; INFECTION PREVENTION; NONHUMAN; PRIORITY JOURNAL; REVIEW; RUBELLA; RUBELLA VIRUS; UNITED STATES; VACCINATION; VIRUS ISOLATION;

ADOLESCENT; ADULT; CHILD; DEVELOPING COUNTRIES; FEMALE; HISTORY, 20TH CENTURY; HISTORY, 21ST CENTURY; HUMANS; PREGNANCY; RUBELLA; RUBELLA SYNDROME, CONGENITAL; RUBELLA VACCINE; UNITED STATES;

EID: 33750346249     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/505950     Document Type: Review

References (64)

1. Gregg NM. Congenital cataract following German measles in the mother. Trans Ophthalmol Soc Aust 1941; 3:35-46.
2. Greenberg M, Pellitteri O, Barton J. Frequency of defects in infants whose mothers had rubella during pregnancy. JAMA 1957; 165:675-8.
3. Manson MM, Logan WPD, Loy RM. Rubella and other virus infections during pregnancy. No. 101. Report on public health and mechanical subjects. London: Her Royal Majesty's Stationery Office, 1960.
4. Lundstrom R. Rubella during pregnancy, a follow-up study of children born after an epidemic of rubella in Sweden, 1951, with additional investigations on proplylaxis and treatment of maternal rubella. Acta Paediatr Scand 1962; 133(Suppl):1-110.
5. Witte JJ, Karchmer AW. Epidemiology of rubella. Am J Dis Child 1969; 118:107-12.
6. Plotkin SA, Oski FA, Hartnett EM, et al. Some recently recognized manifestations of the rubella syndrome. J Pediatr 1965; 67:182-91.
7. Cooper L, Alford CA. Rubella. In: Remington JS, Klein JO (eds) Infectious diseases of the fetus and newborn infant. Philadelphia: WB Saunders, 2001:347-88.
8. Lindquist JM, Plotkin SA, Shaw L, Gilden RV, Williams ML. Congenital rubella syndrome as a systemic infection: studies of affected infants born in Philadelphia, USA. Br Med J 1965; 2:1401-6.
9. Weller TH, Neva FA. Propagation in tissue culture of cytopathic agents from patients with rubella-like illness. Proc Soc Exp Biol Med 1962; 111:215-25.
10. Parkman PD, Buescher EL, Artenstein MS. Recovery of rubella virus from army recruits. Proc Soc Exp Biol Med 1962; 111:225-30.
11. Plotkin SA. Rubella vaccine. In: Plotkin SA, Orenstein WA (eds) Vaccines. Philadelphia: WB Saunders, 2004:707-44.
12. Miller E, Cradock-Watson JE, Pollock TM. Consequences of confirmed maternal rubella at successive stages of pregnancy. Lancet 1982; 2: 781-4.
13. South MA, Sever JL. Teratogen update: the congenital rubella syndrome. Teratology 1985; 31:297-307.
14. Meyer HM, Parkman PD, Hobbins TE, et al. Attenuated rubella viruses: laboratory and clinical characteristics. Am J Dis Child 1969; 118: 155-69.
15. Hilleman MR, Buynak EB, Whitman JE Jr, Weibel RW, Stokes J Jr. Live attenuated rubella virus vaccines: experiences with duck embryo cell preparations. Am J Dis Child 1969; 118:166-71.
16. Prinzie A, Huygelen C, Gold J, et al. Experimental live attenuated rubella virus vaccine: clinical evaluation of Cendehill strain. Am J Dis Child 1969; 118:172-7.
17. Plotkin SA, Farquhar J, Katz M, Buser F. Attenuation of RA27/3 rubella virus in WI-38 human diploid cells. Am J Dis Child 1969; 118:178-85.
18. Plotkin SA, Cornfeld D, Ingalls TH. Studies of immunization with living rubella virus: trials in children with a strain cultured from an aborted fetus. Am J Dis Child 1965; 110:381-9.
19. Plotkin SA, Farquhar J, Katz M, Ingalls TH. A new attenuated rubella virus grown in human fibroblasts: evidence for reduced nasopharyngeal excretion. Am J Epidemiol 1967; 86:468-77.
20. Plotkin SA, Buser F. History of RA27/3 rubella vaccine. Rev Infect Dis 1985; 7(Suppl 1):S77-8
21. Plotkin SA, Norton TW, Cohen BJ, Koprowski H. A type 3 attenuated poliovirus genetically stable after human intestinal passage. Proc Soc Exp Biol Med 1961; 107:829-934.
22. Sabin APSA. Discussion on session V. Proceedings of the International Conference on Rubella Immunization. Amer J Dis Child 1969; 118: 378-80.
23. Hayflick L, Moorehead PS. The serial cultivation of human diploid cell strains. Exp Cell Res 1961; 26:585-621.
24. Barnes EK, Altman R, Austin SM, Dougherty WJ. Joint reactions in children vaccinated against rubella. II. Comparison of three vaccines. Am J Epidemiol 1972; 95:59-66.
25. Kilroy AW, Schaffner W, Fleet WF Jr, Lefkowitz LB Jr, Karzon DT, Fenichel GM. Two syndromes following rubella immunization: clinical observations and epidemiological studies. JAMA 1970; 214:2287-92.
26. Spruance SL, Klock LE Jr, Bailey A, Ward JR, Smith CB. Recurrent joint symptoms in children vaccinated with HPV-77DK12 rubella vaccine. J Pediatr 1972; 80:413-7.
27. Polk BF, Modlin JF, White JA, DeGirolam PC. A controlled comparison of joint reactions among women receiving one of two rubella vaccines. Am J Epidemiol 1982; 115:19-25.
28. Fogel A, Moshkowitz A, Rannon L, Gerichter CB. Comparative trials of RA 27-3 and Cendehill rubella vaccines in adult and adolescent females. Am J Epidemiol 1971; 93:392-8.
29. Harcourt GC, Best JM, Banatvala JE. Rubella-specific serum and nasopharyngeal antibodies in volunteers with naturally acquired and vaccine-induced immunity after intranasal challenge. J Infect Dis 1980; 142:145-55.
30. Naficy K, Nategh R, Ahangary S, Mohsenin H. Artificial challenge studies in rubella: utilization of RA 27-3 rubella vaccines, rubella naturally acquired seropositives, and rubella susceptible children. Am J Dis Child 1970; 120:520-3.
31. Horstmann DM, Liebhaber H, Le Bouvier GL, Rosenberg DA, Halstead SB. Rubella: reinfection of vaccinated and naturally immune persons exposed in an epidemic. N Engl J Med 1970; 283:771-8.
32. Freestone DS, Reynolds GM, McKinnon JA, Prydie J. Vaccination of schoolgirls against rubella: assessment of serological status and a comparative trial of Wistar RA 27/3 and Cendehill strain live attenuated rubella vaccines in 13-year-old schoolgirls in Dudley. Br J Prev Soc Med 1975; 29:258-61.
33. Grillner L. Neutralizing antibodies after rubella vaccination of newly delivered women: a comparison between three vaccines. Scand J Infect Dis 1975; 7:169-72.
34. Weibel RE, Carlson AJ Jr, Villarejos VM, Buynak EB, McLean AA, Hilleman MR. Clinical and laboratory studies of combined live measles, mumps, and rubella vaccines using the RA 27/3 Rubella virus (40979). Proc Soc Exp Biol Med 1980; 165:323-6.
35. Plotkin SA, Farquhar JD, Ogra PL. Immunologic properties of RA27-3 rubella virus vaccine: a comparison with strains presently licensed in the United States. JAMA 1973; 225:585-90.
36. Ogra PL, Kerr-Grani D, Umana G, Dzierba J, Weintraub D. Antibody response in serum and nasopharynx after naturally acquired and vaccine-induced infection with rubella virus. N Engl J Med 1971; 285: 1333-9.
37. Hillary IB, Griffith AH. Persistence of rubella antibodies 15 years after subcutaneous administration of Wistar 27/3 strain live attenuated rubella virus vaccine. Vaccine 1984; 2:274-6.
38. O'Shea S, Woodward S, Best JM, Banatvala JE, Holzel H, Dudgeon JA. Rubella vaccination: persistence of antibodies for 10-21 years. Lancet 1988; 2:909.
39. Bottiger M. Immunity to rubella before and after vaccination against measles, mumps and rubella (MMR) at 12 years of age of the first generation offered MMR vaccination in Sweden at 18 months. Vaccine 1995; 13:1759-62.
40. Johnson CE, Kumar ML, Whitwell JK, et al. Antibody persistence after primary measles-mumps-rubella vaccine and response to a second dose given at four to six vs. eleven to thirteen years. Pediatr Infect Dis J 1996; 15:687-92.
41. Rager-Zisman B, Bazarsky E, Skibin A, et al. The effect of measles-mumps-rubella (MMR) immunization on the immune responses of previously immunized primary school children. Vaccine 2003; 21:2580-8.
42. Freestone DS, Prydie J, Smith SG, Laurence G. Vaccination of adults with Wistar RA 27/3 rubella vaccine. J Hyg (Lond) 1971; 69:471-7.
43. Ray P, Black S, Shinefield H, et al. Risk of chronic arthropathy among women after rubella vaccination. Vaccine Safety Datalink Team. JAMA 1997; 278:551-6.
44. Tingle AJ, Mitchell LA, Grace M, et al. Randomised double-blind placebo-controlled study on adverse effects of rubella immunisation in seronegative women. Lancet 1997; 349:1277-81.
45. Howson CP, Howe CJ, Fineberg HV, eds. Adverse effects of pertussis and rubella vaccines. Washington DC: National Academy Press, 1991.
46. Bar-Oz B, Levichek Z, Moretti ME, Mah C, Andreou S, Koren G. Pregnancy outcome following rubella vaccination: a prospective controlled study. Am J Med Genet 2004; 130:52-4.
47. Best, JM, Castillo-Soloranzo C, Spika JS, et al. Reducing the global burden of congenital rubella syndrome: report of the World Health Organization Steering Committee on Research Related to Measles and Rubella Vaccines and Vaccination, June 2004. J Infect Dis 2005; 192: 1890-7.
48. Anderson RM, May RM. Infectious diseases of humans: dynamics and control. Oxford, UK: Oxford University Press, 1992.
49. Edmunds WJ, Gay NJ, Kretzschmar M, Pebody RG, Wachmann H. The pre-vaccination epidemiology of measles, mumps and rubella in Europe: implications for modelling studies. Epidemiol Infect 2000; 125: 635-50.
50. Ingalls TH, Plotkin SA, Meyer HM Jr, Parkman PD. Rubella: epidemiology, virology, and immunology. Am J Med Sci 1967; 253:349-73.
51. Williams NM, Preblud SR. Rubella and congenital rubella surveillance, 1983. MMWR CDC Surveill Summ 1984; 33:1SS-10SS.
52. Preblud SR, Serdula MK, Frank JA Jr, Brandling-Bennett AD, Hinman AR. Rubella vaccination in the United States: a ten-year review. Epidemiol Rev 1980; 2:171-94.
53. Dudgeon JA. Selective immunization: protection of the individual. Rev Infect Dis 1985; 7(Suppl 1):S185-90.
54. Watson JC, Hadler SC, Dykewicz CA, Reef S, Phillips L. Measles, mumps, and rubella-vaccine use and strategies for elimination of measles, rubella, and congenital rubella syndrome and control of mumps: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 1998; 47(RR-8):1-57.
55. Peltola H, Heinonen OP, Valle M, et al. The elimination of indigenous measles, mumps, and rubella from Finland by a 12-year, two-dose vaccination program. N Engl J Med 1994; 331:1397-402.
56. Castillo-Solorzano C, Carrasco P, Tambini G, Reef S, Brana M, de Quadros CA. New horizons in the control of rubella and prevention of congenital rubella syndrome in the Americas. J Infect Dis 2003; 187(Suppl 1):S146-52.
57. Spika J, Hanon FX, Wassilak S, Pebody R, Emiroglu N. Preventing congenital rubella infection in the European Region of WHO: 2010 target. Euro Surveill 2004; 9:4-5.
58. Cutts FT, Robertson SE, Diaz Ortega JL, Samuel R. Control of rubella and congenital rubella syndrome (CRS) in developing countries, part 1: burden of disease from CRS. Bull World Health Organ 1997; 75: 55-68.
59. Kohler KA, Suleiman AJ, Robertson SE, et al. Immunogenicity of measles and rubella vaccines in Oman: a prospective clinical trial. J Infect Dis 2003; 187(Suppl 1):S177-85.
60. Dayan GH, Zimmerman L, Shteinke L, et al. Investigation of a rubella outbreak in Kyrgyzstan in 2001: implications for an integrated approach to measles elimination and prevention of congenital rubella syndrome. J Infect Dis 2003; 187(Suppl 1):S235-40.
61. Lawn JE, Reef S, Baffoe BB, Adadevoh S, Caul EO, Griffin GE. Unseen blindness, unheard deafness, and unrecorded death and disability: congenital rubella in Kumasi, Ghana. Am J Public Health 2000; 90: 1555-61.
62. Schoub BD, Johnson S, McAnerney JM, et al. Measles, mumps and rubella immunization at nine months in a developing country. Pediatr Infect Dis J 1990; 9:263-7.
63. Hinman AR, Irons B, Lewis M, Kandola K. Economic analyses of rubella and rubella vaccines: a global review. Bull World Health Organ 2002; 80:264-70.
64. Bennett JV, Fernandez dC, Valdespino Gomez JL, et al. Aerosolized measles and measles-rubella vaccines induce better measles antibody booster responses than injected vaccines: randomized trials in Mexican schoolchildren. Bull World Health Organ 2002; 80:806-12.